China’s Great Leap Forward in Biotech (Nikkei Asian Review)

The Nikkei Asian Review explores China’s rapid advances in the field of biotechnology, including gene editing and the use of AI and big data to predict a person’s likelihood of developing a given disease. As Chinese biotech startups push ahead in these areas, venture capital is pouring in from overseas. At the same time, however, scientists and policymakers in developed countries are questioning China’s adherence to ethical standards when it comes to such issues as human trials and access to personal data. READ MORE

Similar Posts:

• China Venture Capital Deals Shrink Amid Regulatory Concerns (Nikkei Asia)
• Barclays: China Fears Being Overplayed (FT Adviser)
• Five Misconceptions About China’s Stock Markets (KraneShares)
• China’s $246B Foreign M&A Buying Spree Is Slowing (Bloomberg)
• EM Push & Pull: As China Rises, Competition for Capital Heats Up (Aviva Investors)
• China Loses #2 Creditor Rank to Germany (Bloomberg)
• India and China Emerging as Startup Hot Spots (Nikkei Asian Review)
• Accounting Fraud and Abuse Still Widespread Among Listed Chinese Stocks (CMN)
• MSCI’s Decision on China’s Onshore Stock Market
• China Has $67 Trillion in Potential Consumer Spending Over the Next 10 Years (Nielsen)
• Understanding China’s Recent Moves in Its Capital Markets (Ray Dalio)
• Russia Pivoted East to Asia 800 Years Before Obama (MT)
• Regulatory Shifts in China: A New Fork in the Road? (The Asset)
• Trade War Steers Chinese Investment Toward Southeast Asia (Nikkei Asian Review)
• What is the SEC Targeting Alibaba (BABA) About? (China Accounting Blog)